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Abstract 
 The prevalence of cancer in modern society has increased from 14.1 million new 
diagnoses and 8.2 million deaths in 2012 to an estimated 21.7 million new diagnoses 
and 13 million cancer-related deaths projected in 2030 [1]. The development of novel 
methods for 3D in vitro tumor growth can help to understand better the progression of 
the disease and eventually provide new therapeutic approaches, especially at the 
personalized medicine level. Human amniotic membrane is a promising biological 
scaffold for the growth of cancer cells and ultimately tumorigenesis. The membrane is 
antimicrobial and contains important extracellular matrix components for cancer cell 
growth. SW-620 colon cancer cells were seeded on the surface of the decellularized 
human amniotic membrane in the presented studies. SW-620 colon cancer cells were 
shown to proliferate on decellularized amniotic membrane in a shortened seeding and 
culturing two day procedure. A five day seeding and culturing on the decellularized 
membrane procedure resulted in a three day proliferative period (days 0 through 3) with 
a 60% seeding efficiency on day 0 (555,000 initially seeded cells). The number of cells 
plateaued from days 3 to 5. These results provide a promising proof-of-concept in 3D in 
vitro monolayer culture. Future work is necessary to improve the use of human amniotic 
membrane as a 3D in vitro scaffold through layering or surface modifications. 
Comparison of the genotypic expression between the in vivo, 3D in vitro amniotic 
membrane and 2D culture models using PCR is also necessary to determine if the cells 
are behaving like cells in physiological conditions.
1 
 
1. Introduction 
Impact of Cancer 
 Cancer is a rapidly-evolving, devastating disease that is projected to be 
diagnosed in 39.6% of men and women in the United States at some point in 
their lives [2]. In 2016, the projections for new cancer cases in the United States 
alone was 1.7 million with roughly 600,000 people perishing from the disease. 
On the global scale, there were an estimated 14.8 million new cases and 8.2 
million cancer-related deaths in 2012 [3]. Cancer has a significant impact on 
global health and is the second highest cause of death in the world. 
 The complexity of cancer, which comprises many different diseases, 
requires extensive research to understand its progression and to improve 
therapeutic treatments.  In the following sections, methods of 2D and 3D cell 
culture and animal models for study of cancer proliferation and metastasis are 
discussed. An overview of colon cancer and the characteristics of the amniotic 
membrane is also included. 
Introduction to Metastasis 
Primary cancer removal is often followed by reappearance of the tumor 
in the same or an alternative site via metastasis. Metastasis is actually the 
predominant cause of cancer-related fatalities. The exact mechanisms of 
metastasis and cause of cancer are still only conjecture, which increases the need 
for cancer-based research.  
Animal Models 
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Currently, animal models are used to study tumor growth and other 
aspects of cancer biology. The predominant animal model used for cancer 
research is the mouse [4]. Specifically, nude mice are used to study the growth 
of human cancers. Zebrafish and rats are also used as animal models for cancer 
research. Mice and other animal models are important to develop studies for 
general cancer research and preclinical research. Animal models represent an in 
vivo system with the cancer behaving similarly to the native environment. The 
limitation of animal models is that even though they are a living system, they do 
not perfectly represent how the cancer develops and progresses in the human 
body. In addition, nude mice have a compromised immune system. Apart from 
the biological differences, tumor size is an additional factor where animal 
models and human patients differ [5]. The maximum size that a tumor can reach 
in a mouse model is much smaller than what would be found in human tumors. 
This can impact the overall growth and metabolic state of the tumor and lead to 
different responses when testing drug efficacy.  
Human Clinical Models 
Human clinical models are also used in modern cancer research, 
especially when studying chemotherapy efficacy on cancer in vivo. The largest 
issues with using humans, especially as a preliminary model to study cancer, are 
finding patients who qualify and are willing to participate in the trial. When 
drugs are fast-tracked into human clinical trials, long term effects and other side 
effects are unknown and may detrimentally impact the patient. Human tumors 
are the most accurate in terms of the actual growth and development of the 
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cancer since the cancer lines being studied are originally derived from humans 
but can be surrounded by ethical obstacles for finding trial participants.  
Personalized medicine is currently evolving to include cancer patients 
with highly diversified tumor characteristics that are otherwise categorized in 
general groups in order to develop therapeutic approaches. Readily available 
primary cancer cells from biopsies make in vitro models, which can be used to 
understand better the response of cancer cells to a variety of chemotherapeutic 
drugs, a potentially powerful tool in rapid screening of anti-cancer agents. 
Cancer treatments formulated in in vitro models will spare the patient from 
unnecessary harm due to aggressive treatment options and observations can be 
made as to which drugs work on a patients’ specific cancer. Individualized 
treatment plans are under development and are being explored through 
immunotherapies and targeted therapies and can be expanded through the 
application of 3D in vitro cancer growth models. 2D and 3D models still need to 
be refined in order to reflect in vivo conditions and be fully manipulated in vitro.  
In Vitro Models 
Modern cancer research has utilized both 2D (monolayer culture on 
tissue culture plates) and 3D in vitro models. The current focus of these models 
is tumor growth, cell migration, cell adhesion, maintenance of in vivo-like 
morphology mimicking the characteristics of gene expression, metabolic state, 
cell-cell interactions of the native tumor microenvironment [6]. 3D in vitro 
models refer to cellular constructs that extend beyond a simple monolayer. They 
can be generated using exclusively cellular aggregates that can grow into tumor 
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spheroids. Alternative approaches include the use of hydrogels to entrap cancer 
cells and allow them to grow in an environment containing components of their 
native extracellular matrix and growth factors [7]. Synthetic and natural 
scaffolds have also been used as they provide extended surface area available for 
cancer cell attachment and growth. Microfluidic networks have also been tested 
in cancer research and they constitute a special category between 2D and 3D 
models [8]. 
2D Static in vitro Culture 
2D in vitro static cell culture involves a culture environment devoid of 
flow and monolayer growth. Generally, static culture is performed in a petri 
dish, flask or well plate and media is supplemented to the container [7]. Static 
culture is beneficial to culture studies since a vast majority of cells can be 
cultured in this way and is widely used due to ease of use. The major weakness 
of 2D monolayer culture is the inability to recreate the 3D nature of actual 
tumors and studies have shown that the lack of three dimensionality 
compromises the phenotypic characteristics of many cancer cell types. Another 
weakness of 2D in vitro cell culture is that there are no extracellular matrix 
components present which limits the extent of which in vitro cancer cells can 
resemble in vivo cellular growth. 
2D In Vitro Culture on Inserts 
One example of a 2D modeling environment is culture on inserts. 
Culturing on inserts is useful when trying to understand angiogenesis, transport, 
cell-cell interactions and invasion [9]. The main premise of cell culture inserts is 
5 
 
that they consist of a thin, porous membrane that allows for the media to pass 
through the membrane [10]. This allows both the lower and upper surface of the 
cells to be exposed to the same nutrients. The membrane can consist of a 
synthetic material of a known porosity. The porosity is meant to mimic in vivo 
conditions due to the fact that surfaces in the body are generally porous to some 
degree and allow for extracellular cell-cell signaling. Some of the common 
materials used for the membrane are polycarbonate, polyethylene terephthalate, 
cellulose esters and polytetrafluoroethylene [9],[11]. These inserts are also used 
to grow co-cultures of different cell types using the same environment. Cells can 
be grown on top of the porous membrane and below the membrane on the 
bottom of the well plate. This allows for cell communication as well as 
controlled co-culturing. One of the main limitations of culturing on cell inserts is 
that the shape of the insert does not resemble the shape of a tumor in vivo. The 
main growth progression is in a monolayer which is not how tumors progress in 
vivo. Culture using cell inserts is a better method of 2D in vitro culture when 
compared to traditional growth in flasks due to the ability to maintain a co-
culture and allow for cell-cell communication, which both mimic in vivo 
conditions.  
3D In Vitro Hydrogel Models 
One 3D culture method is imbedding cells in natural or synthetic 
materials in a hydrogel.  For embedding, cells can either be seeded onto a porous 
surface or entrapped in a hydrogel. Hydrogels can be formed from many 
different materials, both synthetic and natural, and are used to mimic the natural 
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extracellular matrix microenvironment. Some examples of synthetic hydrogel 
materials include: polyethylene glycol, poly(hydroxymethyl methacrylate), 
polyvinyl alcohol, and polycaprolactone [7]. Natural materials include: alginate, 
chitosan, hyaluronan, dextran, collagen and fibrin. Matrigel is another example 
of a naturally-based material. Matrigel primarily contains collagen IV, laminin 
and enactin and was originally derived from Englebreth-Holm-Swarm tumors in 
mice [12]. One potential limitation of a 3D hydrogel tumor model is that cell 
adhesions are not part of the entrapment process. If there is a need to study cell 
attachment, then a hydrogel would be lacking due to the fact that the cells are 
physically trapped and are not required to adhere through their own processes.  
Special precautions are needed when cross-linking is required in 
hydrogel formation. Some chemical cross-linking can be toxic to cells and UV 
or light based cross-linking can also be harmful to the cells [13]. Despite this, 
hydrogels can be tuned to a specific desired environment in terms of the material 
and directional growth for a 3D cell culture.  
3D In Vitro Synthetic Scaffolds 
Synthetic scaffolds are also used as a platform for 3D in vitro cancer 
models. These scaffolds are considered to be a solid scaffold and can be created 
through a variety of methods. This includes 3D printing, electro-spinning and 
other methods to create pores [14]. Some examples of materials that are used to 
form synthetic scaffolds include poly(lactic) acid, poly(glycolic acid) and 
poly(lactic-co-glycolic acid). These specific materials are biodegradable which 
could have mixed results in 3D tumor growth. The positive of biodegradability 
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is that the cancer cells will be able to proliferate and take over the structure 
previously occupied by the scaffold material. On the contrary, the scaffold may 
break down before the tumor architecture is established and bi-products of 
degradation may impact the growth of the cancer and possibly make the culture 
less representative of in vivo conditions. The benefits of synthetic scaffolds as a 
base of cancer cell growth is that they can be reproduced, especially when using 
a 3D printed scaffold. The same template can be used to create more scaffolds 
with specific parameters and porosity. A limitation of using synthetic scaffolds 
is that the scaffold can influence the directionality of cellular growth and result 
in deviations from in vivo-like growth patterns. They also do not contain 
extracellular matrix components and are considered inert in terms of interactions 
with the cells. Research in our lab (Cortes/McKernan/Sikavitsas, unpublished) 
demonstrated a lack of adhesion and growth of cancer cells seeded on 3D 
printed poly(lactic acid) scaffolds as well as electro-spun poly(lactic acid) 
scaffolds. The cancer cells were not able to bind to either of these scaffolds in a 
48-hour period even when adhesion peptides (RGD) were incorporated on the 
poly(lactic acid) surface.  
3D In Vitro Natural Tissue Models 
Scaffolds derived from natural tissues also demonstrate promise as a 3D 
culture platform. Especially for human-derived tissues, the propensity to support 
cellular growth and proliferation is evident [7]. They contain an extensive 
network of extracellular matrix components that promote cell binding. Specific 
examples of natural-derived tissues used in current research include the small 
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intestine submucosa (SIS), human umbilical vein (HUV) and amniotic 
membrane to name a few [15]. Natural materials can be decellularized before 
seeding with new cells since the presence of the preexisting cells if often 
undesirable with the exception of cases where co-cultures of cancer cells are 
explored. The decellularization process results in some damage to the native 
architecture of the extracellular matrix; however, cells can still favorably adhere 
to the decellularized tissues using the extracellular matrix components which 
still closely resemble the native state. Specifically, the human amniotic 
membrane is a thin material that seems to resemble a 2D environment as 
opposed to a 3D environment. This can be remedied by layering membranes on 
top of each other to increase the scaffold thickness. Cells can be seeded between 
the layers to also improve cell growth in three dimensions. Significant 
limitations include individual variation as well as reliable sourcing. Natural 
materials, especially of human nature, can be difficult to source. Individual 
variation is a challenge and variability in sample size is almost impossible to 
eliminate. 
Co-culture Using Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) have been thought to impact the growth 
of tumors in vivo through cellular communication. The impact of MSCs on 
tumor growth is questionable due to the fact that many studies have 
demonstrated that they increase growth and many others have demonstrated that 
they inhibit growth [16]. Stem cells can promote tumor growth by means of 
differentiating into pericytes or endothelial cells involved in angiogenesis. The 
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secretion of VEGF by the MSCs also helps to promote angiogenesis within the 
tumor. Tumor cells can communicate with MSCs and other cells within the 
tumor by use of extracellular vesicles [17]. This communication method is two-
way with both the MSCs and tumor cells able to produce extracellular vesicles. 
The vesicles contain non-coding RNA (ncRNA) which influences cancer 
initiation, progression and pre-metastatic niche formation. MSCs are also 
involved in immune suppression of B and T lymphocytes and natural killer cells 
[16]. This allows for the tumor to continue with growth and proliferation with 
only limited immune resistance. It is also believed that MSCs can influence and 
control the epithelial-to-mesenchymal transition (EMT) which leads to increase 
metastasis and invasiveness. The inhibition/increase discrepancy may be 
partially due to the timing of MSC introduction into the tumor. Some studies 
demonstrate that introducing MSCs to established tumors inhibits the growth of 
the tumor. Other studies demonstrated that the addition of MSCs with cancer 
cells improved tumor formation.  Introducing MSCs with cancer cells at the 
beginning of growth may be useful to promote angiogenesis and tumor 
proliferation in 3D in vitro models. 
3D In Vitro Tumor Spheroids 
 Currently, 3D cancer models have focused on several different materials 
and experimental designs. Some examples include culturing multicellular 
aggregates (spheroids), hydrogels, synthetic scaffolds and seeding cells on 
natural tissue.[6]. Maintaining the health of cancer spheroids over time is a 
challenge. As the spheroid expands in the radial direction due to cell 
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proliferation, the spheroid becomes more tightly packed with cells in the interior 
experiencing hypoxia [18]. The transport limitations of spheroids result in a 
rapidly expanding mass due to direct contact with the media and nutrients and a 
necrotic center that has little to no access to vital nutrients. One benefit of the 
spheroid is the natural form that it takes as it grows. Spheroids are aggregated so 
that the tumor-like form already exists as the cells proliferate. A downfall to a 
tumor spheroid model is that in the purest form, there is not existing 
extracellular matrix. Apart from this, the tumor size is limited in the radial 
direction due to the transport limitations that occur without angiogenesis.  
 
Goal of Study 
The main point of this study is to determine the growth and proliferation 
of cancer cells seeded on a decellularized human amniotic membrane. The 
amniotic membrane was specifically chosen for this application due to 
accessible sourcing as well as being human-derived. The cancer line that has 
been used is the SW-620 colon cancer cell line. The results of this aim will be 
developing preliminary model for future work involving surface modification 
and 3D cancer cell growth using the amniotic membrane.  
Colon Cancer Overview/Motivation 
Colon cancer is the third most common type of cancer found throughout 
the world for both sexes [19]. There are more than a million new cases each 
year, with roughly half of those cases being fatal. In this study, the SW-620 
colorectal adenocarcinoma cell line was chosen due to the resemblance of the 
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amniotic membrane to the mucosa of the colon. This line was also chosen due to 
its rapid proliferation rate. 
Colon Cancer Staging and Treatment 
Colon cancer is classified using a staging system. Stage 0 refers to 
carcinoma in situ, or a grouping of abnormal cells located in the intraepithelial 
or lamina propria of the colon [20]. Stage 0 is the lowest stage classification for 
colon cancer. The worst and most progressed stage of colon cancer is stage 4. 
Stage 4 is uniquely characterized by metastasis to either 1 or multiple other 
organs. The primary tumor can be in any classification and the lymphatic system 
has been invaded to some extent.  
 
Figure 1: Colon cancer polyp [21] 
The tumor initially appears as a small polyp (Figure 1) which can either 
be benign or malignant [21]. Polyps can be discovered through a routine 
colonoscopy performed by a physician. Some benign tumors have the ability to 
become malignant so surgical removal of abnormal polyps is advised. If not 
surgically removed, the polyps can grow in size to cause physical discomfort 
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along with other gastrointestinal abnormalities. Typically, colon cancer survival 
has not improved despite advances in chemotherapies and radiation-based 
treatments. The survival rate ranges from 90% in the initial stage 0 to stage 2 
detection on a 5-year basis [22],[23]. The rate drops to as low as 10% for 5-year 
survival when detected at stage 4 metastasis. Tumor excision through surgery 
allows for this high rate of 5-year survival for the lower stage patients [22]. 
Stage 4 colorectal cancers are generally treated with chemotherapy. Drugs that 
are currently on the market consist of 5-fluorouracil, leucovorin and several 
others. Some drugs are now utilizing targeted approaches using monoclonal 
antibodies. These drugs specifically target the epidermal growth factor receptor 
(EGFR) to slow or stop the rate of metastasis. Others are able to inhibit growth 
and development pathways needed for cancer metastasis. Bevacizumab targets 
the VEGF system when used in combination with other chemotherapy drugs 
[24]. Targeting the VEGF pathway is important to limit tumor growth. VEGF is 
responsible for controlling angiogenesis in healthy cells and is upregulated in 
cancer cells [25]. Limiting the development of new blood vessels in cancerous 
tumors ensures that the cells on the interior of the tumor do not receive proper 
nutrients. Tumors rely on a network of blood vessels for nutrient transport and 
are not sustainable through nutrient diffusion processes alone.  
Colon Cancer Metastasis Mechanisms 
Current mechanisms for metastasis in cancer cells include the influence 
of cancer stem cells (CSCs) [22]. It is not known if these cells mutate from 
healthy sources of stem cells or if cancer cells have the ability to dedifferentiate 
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into CSCs. Regardless of source, CSCs are responsible for the tumorigenic and 
metastatic properties of cancer cells. In epithelial cell cancers, cells undergo 
epithelial-to-mesenchymal transition and obtain properties similar to stem cells 
[22],[23]. These properties include infinite proliferation, self-renewal and 
apoptotic resistance. EMT is the critical step in order for cancer cells to expand 
from a primary grouping of abnormal cells to a metastatic phenotype with the 
ability to travel to distant locations in the body. EMT is also characterized by 
increased drug resistance and the down regulation in production of E-cadherin. 
The loss of E-cadherin allows the cells to separate in attachment to neighboring 
cells and migrate throughout the body. This process occurs relatively quickly in 
colorectal cancers and contributes to the aggressiveness and poor prognosis of 
metastatic stage 4 cancer. The metastatic colon cancer cells invade the basement 
membrane and are able to invade both the lymphatic and circulatory system. 
This allows for them to traverse the lumen of the vessels (intravasation) and exit 
the lumen (extravasation) to reach other organs and produce new tumors. 
Overview of the Amniotic Membrane 
The amniotic membrane, or amnion, is a thin, extraembryonic membrane 
of the placenta that functions as an immune barrier to the fetus [26]. The 
chorionic membrane, or chorion, is found on the outside of the amniotic 
membrane and is also part of the placenta. The amniotic membrane is composed 
of several different components including: fibronectin, elastin, nidogen, collagen 
I, III-VI, elastin and hyaluronic acid. These components are generally found as 
part of the extracellular matrix of many cells. The amniotic membrane is 
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compatible with many different ECM components and ideal as a tissue 
engineering scaffold due to its low immunogenicity. The DNA of the membrane 
epithelial cells contain Fas L, TNF and TRAIL which are all genes that induce 
apoptosis. These genes can cause leukocytes to commence apoptosis which 
reduces the effectiveness of an immune response against the amniotic 
membrane. The amnion is also antiangiogenic and is avascular in nature. The 
amniotic membrane is antimicrobial due to its production of β-defensins which 
kill invading microbes. The anti-inflammatory properties derive from the 
suppression of cytokines that cause inflammation as well as IL-1α and IL-1β 
expression. The cells of the amniotic membrane also produce secretory 
leukocyte proteinase inhibitor and elafin which also contribute to the anti-
inflammatory properties. The combination of these factors make the amniotic 
membrane an ideal choice as a scaffold material for tissue engineering. The 
membrane also maintains its mechanical strength and shape even after excision 
from the placenta and chorion and after the decellularization process. This 
enhances the stability as a scaffold material. The membrane is also 
semipermeable which could assist nutrient diffusion or cellular penetration. 
Literature states that its thickness ranges from 70-180 μm in thickness which 
could be  plausible for cells to traverse or permeate [26]. Stacking of the 
amniotic membrane has also been utilized with cell seeding to create an 
improved 3D in vitro scaffold (Mathilde/Nollert, thesis). 
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2. Materials 
Cell Line 
SW-620 
The SW-620 cell line is derived from a 51 year old male Caucasian 
patient [27]. The cells were harvested from the lymph node (metastatic site) 
after the original colorectal adenocarcinoma spread. The characterization of 
disease progression was Duke’s type C. The cell line is considered to be 
adherent epithelial cells but these specifically have already gone through 
metastasis. These cells were purchased in September 2016 from American Type 
Culture Collection (ATCC) and delivered in a frozen state. They were cultured 
and expanded to grow the cell stock when they arrived in November 2016. Extra 
cells were frozen and stored in liquid nitrogen until needed for culture. To date, 
these cells have only been cultured for DNA quantification and for seeding on 
the amniotic membrane. 
Amniotic Membrane 
  Amniotic membranes used in this thesis were sourced from Norman 
Regional Hospital in Norman, OK. These amniotic membranes were 5 days old 
when donated at no charge. Specifically, the membranes in this thesis were 
processed by Julian Arrizabalaga in October 2016 and decellularized by him.  
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3. Methods 
Cell Culture 
SW-620 
The SW-620 cells were cultured in accordance to the guidelines set in 
place by the ATCC with some slight modifications [27]. Cells taken from 
cryopreservation in liquid nitrogen were thawed in a water bath and added to a 
Falcon tube, supplemented with Leibovitz’s L-15 media (Life Technologies ™). 
This Falcon tube was then centrifuged for 5 minutes at 1100 rpm. The 
supernatant was pipetted out of the Falcon tube and the concentrated cells were 
re-suspended with L-15 media to a concentration of 1 million cells/mL. The 
supernatant was removed in this process in order to remove any DMSO which is 
toxic to cells in general [28]. In each T-75 flask, 1 mL of cell and media mixture 
was added. Each flask was supplemented with another 9 mL of L-15 media to a 
final flask volume of 10 mL. 
For general culture and expansion, the cells were rinsed with 3 mL of 
PBS per flask the day after plating. The PBS was suctioned out with a pipette 
and 10 mL of L-15 media were added to the flask. After this step, media was 
changed every 3 days (2 days between each media change). Media changes were 
continued until cells reached 85-90% confluent on the bottom of the flask. The 
splitting procedure is documented in the section following the culture of PC3 
cells. SW-620 cells were split using 1:4 to 1:10 ratio of original flasks to new 
flasks needed.   
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SW-620 cells were prepared for cryopreservation by splitting the cells 
and re-suspending the cells using cryogenic media. 1 mL of the cell media 
mixture with a concentration of 1 million cells per 1 mL was placed into each 1 
mL cryogenic tube. Tubes were placed in a slow, controlled freezing container 
and placed in a -80°F freezer overnight. The next day, tubes were taken and 
placed in cryogenic storage tanks for long-term storage. 
Splitting 
 Splitting a cell culture, or subculturing, refers to removing the cells from 
the original flask and moving them into new flasks to expand their growth. 
There are several important factors to determine the correct time to split a cell 
culture [28]. Confluence, or the cell monolayer density on the bottom of a flask 
or culture vessel, is a prime indicator of when to split. This can be visually 
determined using a light microscope and is characterized by high cell density 
and little to no areas of space without cells. When cells reach confluence, they 
need to be split within a 24 hour period or else there is a risk of apoptosis and 
longer recovery when the flasks are subcultured. Timing is also an indicator of a 
subculture requirement. Yield and growth are consistent as long as the seeding 
density is maintained and should occur over a set time period. Each cell line has 
different timing requirements and multiplication times. Confluence and timing 
are the most used methods of determining when a cell culture should be split 
within this lab and this thesis.  
 Splitting requires several different materials and is based on a 
standardized protocol within the Sikavitsas lab with minor adjustments. Media, 
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trypsin and PBS must first be brought to temperature in a 37°C water bath. The 
specific media used is the same media used for culture of a particular cell line. 
Once they are up to temperature, cells are placed under the Bio-Hood and the 
existing media is suctioned out of the flask. 3 mL of Dulbecco’s phosphate 
buffered saline (PBS, Life Technologies™) is added to each culture flask and 
gently flowed over the bottom of the flask. This step removes any existing 
debris or serum that can inhibit the action of trypsin [28]. The PBS is then 
suctioned out of each flask and 2 mL of trypsin is added to each flask. This is 
gently rinsed over the bottom of the flask to ensure contact with the entire cell 
monolayer. Flasks are then incubated at 37°C and the designated CO2 setting for 
5 minutes. After this incubation period, fresh media (8 mL/flask) is added to the 
trypsin and used to rinse the monolayer and suspend cells in the media mixture. 
This rinse is repeated by suctioning and flowing the media along the bottom of 
the flask. After roughly 15 rinses using the same media, the media, trypsin and 
cell suspension is taken out of the flask and placed in a Falcon tube for 
centrifugation. If the total cell/media/trypsin volume is under 15 mL, a 15 mL 
Falcon tube is used for centrifugation. If the total cell/media/trypsin volume is 
under 50 mL and greater than 15 mL, a 50 mL Falcon tube is used for 
centrifugation. More Falcon tubes can be used if the total volume exceeds 50 
mL.  
A small, well-mixed sample (<1 mL) is taken from the Falcon tube in 
order to be counted. Cells were counted using a hemocytometer. 20 μL of the 
well-mixed cell/media sample was combined with 20 μL of trypan blue and 
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mixed. A glass cover slip was placed on top of the hemocytometer and 10 μL of 
the trypan blue/media mixture was pipetted into each side of the hemocytometer. 
Cells were counted on both sides of the hemocytometer. Live cells appeared as 
bright, white circles under the microscope. The specific counting protocol is 
found in Appendix 11. 
The Falcon tube is spun at a speed of 1100 rpm for 5 minutes until a cell 
pellet forms at the bottom of the tube. All supernatant is suctioned out using a 
sterile glass pipette, leaving a small amount of media directly around the cell 
pellet. Cancer cells have a tendency to not pack as tightly as other cells and can 
result in cell loss if the small amount of media is not maintained around the 
pellet at this step. The cells are resuspended to a concentration of 106 cells/mL 
of fresh media and pipetted so that 1 mL of cell resuspension is placed in each 
new flask. This is supplemented with 9 mL of fresh media so that each flask 
contains a total volume of 10 mL. The splitting ratio differs between cell lines 
and is discussed for each cell line in the cell culture section of this thesis. 
Decellularization of Amniotic Membranes 
This protocol is the current protocol for amniotic membrane 
decellularization in Dr. Nollert’s lab and was performed by Julien Arrizabalaga 
to prepare all amniotic membranes used in this thesis. The decellularization 
protocol is found in Appendix 12. 
The first steps of the decellularization protocol involved removing the 
amniotic membrane from the chorionic membrane and rest of the placenta. This 
is performed by blunt dissection by hand. Once the amniotic membrane is 
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isolated, the umbilical cord is removed for other projects and the rest of the 
placenta is discarded as biohazard. The membrane is placed in a beaker of 
distilled water to removed blood and swell the spongy layer. The membrane is 
placed on a flat tray with the stromal side facing upwards. The spongy layer on 
top of the stromal side is removed by hand to not destroy the actual membrane. 
Using a 3D printed rectangle template (6.5 cm by 9.5 cm), the membrane was 
cut into smaller rectangles using a scalpel. A small cut was made at the bottom 
left hand corner of each rectangle in order to differentiate the top from the 
bottom. The membranes are placed in a 250 mL bottle and placed in the -86°C 
freezer for two hours. At the end of the two hour freeze, they are placed in the 
water bath at 37°C for 15 minutes and frozen/thawed again. After the second 
thaw, membranes are rinsed with distilled water and transferred to a 500 mL 
bottle filled with 400 mL of distilled water and 0.03% (w/v) sodium dodecyl 
sulfate. These bottles are then placed on an orbital shaker for 12-24 hours at 100 
rpm. Membranes are washed in new bottles of 400 mL of distilled water and 
transferred to new bottles at 5, 15 and 40 minutes and 1, 6 and 24 hours. In order 
to remove residual DNA, membranes are incubated with 20-50 μg/mL DNase in 
a Tris buffer solution on an orbital shaker for 2 hours at 100 rpm. Membranes 
are then rinsed with distilled water. To sterilize the membranes, they are placed 
in a solution of 0.2% (v/v) peracetic acid and 4% ethanol in distilled water for 2 
hours on an orbital shaker at 100 rpm. The bottles are wrapped in aluminum foil 
to maintain sterilization activity of the peracetic acid. Under the Bio-Hood, the 
membranes are washed in sterile distilled water at 100 rpm for 10, 20 and 30 
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minutes. They are washed again for 24 hours in distilled water at the same 
orbital shaker conditions. After the final distilled water wash, membranes are 
transferred into sterile PBS and the pH is recorded right after transfer and after 
24 hours and should be in the biological pH range (7.2 to 7.4). The membranes 
are transferred into a final sterile PBS solution with antibiotics and stored in the 
4°C refrigerator until needed. 
Static Membrane Growth 
Decellularized amniotic membranes were obtained from Julian 
Arrizabalaga and Jin Liu from Dr. Nollert’s research lab. The decellularization 
protocol was performed by Julien and sterile, decellularized membranes were 
placed in PBS for storage in the 4°C refrigerator. These membranes were placed 
in the PBS in October 2016. 
Membranes were prepared the day before cell seeding for both cell 
growth studies. Stainless steel A4 washers (also provided by Julien and Dr. 
Nollert’s lab) were sterilized in batches of six in the anprolene sterilizer for 12 
hours. Tools were also sterilized in the same batch as the washers. Specific tools 
included a pair of curved hemostats, a scalpel handle, a pair of scissors, a large 
forceps, beakers and a large petri dish. Membranes were taken from the sterile 
PBS and placed on the large petri dish using a large forceps. This was done one 
at a time to avoid crowding or contamination. The cut corner of each membrane 
was oriented so that the cut corner was on the bottom left side of the membrane. 
This ensures that cells are seeded on the correct side of the membrane. A 3D 
printed square template was placed on the membrane and the scalpel equipped 
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with a sterile blade was used to cut out small squares of membrane. The 
dimension of this template and the approximate dimensions of the membrane 
was 2.5 cm X 2.5 cm. The total surface area of the cut membrane was 6.25 cm2. 
The measured thickness of the amniotic membrane (n=1) was 86.6 +/- 6.1 μm in 
the laboratory. This value was measured by taking ten different measurements 
on various parts of a decellularized membrane using an iGaging® micrometer. 
The micrometer measures to an accuracy of +/- 4 μm. Each square was 
transferred into a sterile, non-tissue culture 6-well plate with care taken to 
ensure that the correct side was facing upwards. A washer was carefully placed 
on top of the flattened, square membrane in each well plate (Figure 2). The 
washer thickness, outer diameter and inner diameter dimensions were 0.2, 3.4 
and 2 cm, respectively. The resulting exposed membrane surface area for cell 
seeding was 3.14 cm2. The washer is not biologically reactive with the 
membrane or cells and is used to keep the membrane flat and stable on the 
bottom of the well plate.  
 
Figure 2: Stainless steel washer 
This process was continued until all well plates were filled with 
membrane squares and washers. Each well was supplemented with 5 mL of L-
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15 media. All well plates were placed in the incubator at 37°C and atmospheric 
CO2 overnight to bring to temperature. 
 
Figure 3: Representative 6-well plates with membranes 
On the day of seeding, the cell flasks were split according to the splitting 
protocol. Cells were counted using the hemocytometer and trypan blue staining. 
Each cell-seeded membrane was seeded with 500,000-1,000,000 cells per 0.15 
mL. Control membranes were not seeded with cells and were supplemented with 
L-15 media. The first seeding was done with the initial concentration of cells in 
the volume of 0.15 mL placed directly on the membrane in the inner circle of the 
washer. All well plates were then incubated in the 37°C and atmospheric CO2 
incubator for an hour. After the hour, membranes were reseeded by taking the 
supernatant from the sides of the washer and pipetting it back onto the center of 
the membrane. At this time, media was placed in the water bath to bring up to 
37°C. Well plates were incubated for another hour and reseeded at the end of 
that hour. In total, there were 3 seeding periods and 2 hours of incubation. After 
the last seeding period, 5 mL of L-15 media was pipetted carefully and slowly 
onto the top of each washer. By placing media onto the washer, cells were less 
likely to be washed off due to the media while still filling the well with media. 
The media flowed off of the washer and over the amniotic membranes. The day 
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0 sample was taken at this point. All other well plates were placed back into the 
incubator until samples needed to be taken.  
For the static membrane growth experiments, the SW-620 cell line was 
used. This explains why L-15 media was used for all static membrane 
experiments. Sample sets were taken in triplicate. The sampling process requires 
a pair of hemostats or forceps and a pair of scissors. The washers are removed 
from the wells and placed on a petri dish. One at a time, the amniotic membrane 
is lifted from the well using the hemostats and cut into small pieces using the 
scissors. The small pieces are placed into a small sample tube filled with 1 mL 
of nanopure water. Once all the samples are placed in their respective collection 
tubes, they are sonified for 5 seconds each. 200 μL of trypsin is added to each 
collection tube under the Bio-Hood. They are then incubated for 1 hour in the 
37°C/atmospheric CO2 incubator. Following the incubation step, samples are 
sonified for 10 seconds each and placed in the -20°F freezer until the 
freeze/thaw cycles can be completed. 
Overview of the Five Day Membrane Study 
Media changes were performed on day 2 (before the sample) and on day 4 (after 
the day 4 sample and before the day 5 sample). This would ensure that cells are 
favorably adhering to the membrane and can withstand a media change. The 
SW-620 cells were still used for the study. A total of 555,000 cells suspended in 
0.15 mL of media was seeded onto each cell-seeded, experimental membrane. 
No fixed samples were taken during the trial in order to save resources and only 
focus on growth in terms of DNA content present per membrane. 
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Sampling: Two Day Membrane Study 
Day 0 samples were taken immediately following the third seeding 
period. A total of 3 DNA assay samples were taken and processed according to 
the DNA assay preparation protocol per day for membranes seeded with cells. 
Two DNA assay samples were taken on both day 0 and day 2 for the membranes 
without cells. On all sample days, 3 membrane samples were taken and fixed for 
the membranes seeded with cells. A fixed sample was taken on day 0 and day 2 
for membranes not seeded with cells. The samples were fixed by gentle 
submerging into PBS 3 times and then placed in fixing solution (10% formalin 
in PBS (v/v)) for 15 minutes. After the 15 minute period expired, samples were 
placed in a labelled collection tube filled with 1 mL of 70% ethanol and stored 
in the refrigerator. 
Sampling: Five Day Membrane Study 
For each day of sampling, three samples were taken and processed 
according to the DNA assay protocol for each experimental group. For example, 
on day 0, there were three samples taken for the control (no cell) group and three 
samples take for the experimental (SW-620) group. Each sample was analyzed 
in triplicate during the DNA assay and averaged together to get the final value. 
This was different from the first experiement in that each day sample had a 
corresponding control sample for accuracy. 
Method of Analysis 
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DNA Assay 
 Preparing the sample for analysis differs slightly when analyzing a tissue 
material versus a synthetic scaffold. For the amniotic membrane scaffolds, 
samples to be used for DNA assay were taken according to the lab protocols 
found in the Sikavitsas lab. This specific protocol can be found in Appendix 6. 
Each membrane scaffold was taken from the well and cut into small pieces using 
scissors. The small pieces were placed in a small sample tube in 1 mL of 
nanopure water. Each sample was then sonified for 5 seconds. After sonication, 
200 μL of trypsin was added to each sample tube. The samples were then 
incubated at 37°C and atmospheric air conditions for 1 hour. The reason that 
they were incubated in atmospheric air was because the SW-620 cells are 
cultured in that condition. Following the hour of incubation, samples were 
sonified again for 10 seconds each and placed in the -20°C freezer. 
 The samples being assayed were taken out of the freezer and allowed to 
thaw at room temperature. During this period, the DNA standards were prepared 
using a serial dilution method. Standard 4 was prepared to a concentration of 3 
μg/mL by combining 30 μL of DNA standard and 970 μL of nanopure water. 
For consistency, the serial dilution was performed in the same manner for each 
assay needed in this thesis but it could be calculated to make different volumes 
of each standard by using the C1*V1=C2*V2 equation for dilutions. To ensure 
proper concentrations, each standard was vortexed for a few seconds before 
proceeding to the next standard. To make standard 3, 700 μL of standard 4 was 
added to 1.4 mL of nanopure water.  Standard 2 was prepared by adding 1 mL of 
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standard 3 to 2.8 mL of nanopure water. Finally, standard 1 was prepared by 
adding 2 mL of standard 2 to 4 mL of nanopure water. The final concentrations 
of standards 1, 2 and 3 were 0.1, 0.3 and 1 μg/mL respectively. Standard 0 
simply consists of pure nanopure water. 
 The buffer solution was prepared according to the “DNA Assay” 
protocol sheets found within the lab. Appendix 4 includes the protocol for 
preparing the buffer solution as well as preparing the well plates for assay. The 
amount of buffer varied with the amount of samples being analyzed. The 
volume amount of 20X TE buffer solution and amount of nanopure needed to 
dilute to a 1X buffer was listed on the assay sheet. Once the buffer was mixed, 
half of the volume was transferred to another container. The secondary container 
was wrapped in foil to protect from the light and set aside to be mixed with 
PicoGreen later on. 
 A DNA assay was preformed using an Invitrogen™ Quant-iT™ 
PicoGreen™ dsDNA Assay Kit [29]. Opaque 96-well plates were prepared and 
the layout of the well plate was drawn in the lab notebook to ensure accuracy 
and precision. Initially, 107 μL of buffer solution (the half not wrapped in foil) 
was pipetted into each occupied well. This includes wells occupied by the 
standards. Before adding samples or standards to the wells, each was vortexed 
gently to ensure homogeneity. Once mixed, 43 μL of sample or standard was 
added to the designated wells. Each sample/standard was analyzed in triplicate. 
The assay protocol sheets also included the amount of PicoGreen needed for the 
number of samples. The designated volume of PicoGreen was added to the 
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buffer half wrapped in the foil. This set was performed in the dark since 
PicoGreen is light sensitive and premature exposure to light skews the results of 
the assay. Once the PicoGreen buffer solution was vortexed, 150 μL was added 
to each occupied well. The plate is covered for 5 minutes with foil to set before 
running through the spectrophotometer/fluorometer. 
Population Doubling Rate 
 The population doubling rate was calculated using the results of the 
DNA assay and confirmed using the microscope images in Figure 5. The cell 
number determined from the assay was multiplied by two to determine the 
doubled population. The amount of time to reach population doubling was then 
interpolated using the assay results (values with cell numbers between the 
doubled day 0 value) and the calculated doubled population for day 0. 
Statistical Analysis 
Statistical significance was determined using the T-test Excel built-in 
function. A star above the bars in the graph signifies a p-value of less than 0.05. 
Error bars represent the standard deviation for each sample. 
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4. Results 
Static Amniotic Membrane Culture 
Experiment #1: Two Day Culture 
The first experiment was a true proof-of-concept trial to determine if the 
SW-620 cells were viable when seeded on the decellularized amniotic 
membranes. The seeding concentration per membrane was 106 cells/membrane. 
The 106 cells were contained in 0.15 mL of media which was seeded onto each 
membrane.  
 
Figure 4: Two day static membrane experiment with SW-620s; dashed line represents the initial number of 
cells seeded 
 The results of the DNA assay for the day 0 controls, the day 2 controls 
and the days 0-2 cell-seeded samples are depicted in Figure 4. A substantial 
number of cells were lost and did not adhere from the initial seeding to the time 
of the day 0 sample collection. The values did begin to increase after the initial 
drop between seeding and day 0.  
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Experiment #2: Five Day Culture 
 The pilot study was repeated and expanded from two days to five days. 
Images were also taken for a visual representation of the cell proliferation on the 
membrane. Figure 5 tracks the progress of SW-620 cell growth from before the 
day 1 sample up until right before the day 5 sample. The same wells (day 5, 
middle no cells and day 5, middle cells) were imaged over the course of the 
entire experiment for consistency.  
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Day 1 Day 2 
Day 3 Day 4 
Day 5 
Figure 5: Days 1-5 static membrane growth seeded with SW-620 cells 
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Day 1 Day 2 
Day 3 Day 4 
Day 5 
Figure 6: Days 1-5 static membrane controls without cells 
33 
 
 
Figure 6 shows the images taken of the control membranes without any cells. No 
growth appears on the surface and no cross contamination of cells ended up on the 
control membranes.  
 
Figure 7: Day 5 amniotic membrane without cells 
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Figure 8: Day 5 amniotic membrane seeded with SW-620 cells 
Figures 7 and 8 are higher magnification images (using the 20X setting 
on the light microscope) of day 5 right before samples were taken. The surface 
architecture of the membrane can be observed on the membrane without cells. 
The membrane with cells shows about a 70-80% confluency of cells on the 
surface. Cells can be seen throughout the entire surface of the membrane.  
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Figure 9: Five day static membrane experiment with SW-620s; dashed line represents the initial number of 
cells seeded 
 There were 555,000 SW-620 cells initially seeded onto the membrane 
with an observed seeding efficiency of 60% on day 0 as observed in Figure 9. 
There was a significant increase in the mass of DNA per mg of tissue between 
days 0 and 1 as well as days 1 and 2. The DNA mass per mg of tissue values 
plateaued from days 3 to 5, with no significant increase or decrease over these 
days. There was a 300% increase in the mass value of DNA per mg of tissue 
comparing the value for day 0 to day 5. The population doubling rate of the SW-
620 cancer cell seeded on the amniotic membrane was estimated to be between 
1 and 2 days.   
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5. Discussion 
Static Amniotic Membrane Culture 
 The main goal of this study was to determine the seeding efficiency and 
proliferation of SW-620 cells seeded and cultured on the surface of 
decellularized human amniotic membrane. The amniotic membrane cancer cell 
cultures are critical proof-of-concept experiments (Figures 4 and 9) that will 
potentially lead to more extensive investigation of the use of the human amniotic 
membrane as a 3D in vitro cancer model. The experiments presented include 
visual images of the membrane (Figures 5-8) and are able to confirm the 
proliferation of SW-620 cancer cells on the surface of the membrane. From the 
top down view, cells can be viewed forming a monolayer on the surface of the 
membrane. Media changes that often pose cell detachment if cell adhesions are 
weak, did not seem to impact the adhesion or growth of the cancer cells on the 
surface of the amniotic membrane. Increasing the extent of the culture period 
can help to determine if cells are able to eventually organize into a small tumor 
on the human amniotic membrane.  
 Colon cancer tumors begin as small polyps on the surface of the lining of 
the colon. This is a flat, long environment since the mucosa of the colon extends 
along the circumference and length of the colon. The human amniotic membrane 
can physiologically resemble this flat environment. The possibility of seeding 
healthy colon endothelial or mucosal cells on the membrane first and then 
introducing the colon cancer cells may even be able to accelerate the 
tumorigenesis process and allow the exploration of colon cancer cells with 
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healthy cells residing in that microenvironment and may be critical in tumor 
formation or metastasis. 
 Figures 5 and 6 depict images of the decellularized amniotic membrane 
over the five day culture period. Figure 5 represents the membranes that were 
seeded with SW-620 cells and Figure 6 shows the membranes that were not 
seeded with cells. Cells appear as rounded shapes with slightly darker nuclei. 
Cells can be seen proliferating in a monolayer in Figure 5. The images of the 
membranes that were not seeded with cells only display the surface architecture 
of the membrane and do not contain any rounded cell shapes. This signifies that 
there was no cross contamination of cells to the control membranes. Figures 7 
and 8 provide a view of the amniotic membrane before the day 5 sample was 
taken (on day 5) zoomed at 20X magnification. Figure 7 depicts the control 
membrane and Figure 8 depicts the membranes seeded with SW-620 cells. Cells 
in Figure 8 can be differentiated from the surface architecture of the membrane 
in Figure 7 in that the cells appear as consistently small and rounded figures. 
The surface of the membrane appears irregular in shape and not small, round 
shapes. The cell monolayer in Figure 8 is nearly confluent, which is a promising 
result in the proliferation of SW-620 cancer cells on the amniotic membrane. 
 One metric that can be used to compare the growth of the SW-620 cells 
in vitro on the amniotic membrane to in vitro 2D flask cultures and in vivo 
tumor growth is the population doubling rate. The doubling rate is most accurate 
when measured before the culture reaches high levels of saturation. This is done 
to limit the amount of impact that cell crowding has on the proliferation rate. 
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Using the DNA assay results and images taken through the light microscope of 
the amniotic membrane, the population doubling rate can be estimated. For the 
in vitro amniotic membrane culture, the population doubling rate was 
approximately measured to be between 1 and 2 days (30 hours, Figure 9). Using 
Appendix 14 (2D culture growth of SW-620 cells) and literature cultures, the 
population doubling rate for 2D flask culture is 26 hours [30]. A study growing 
SW-620 tumors in Rowett athymic rats determined that the doubling rate in vivo 
was 5.5 days [31]. The value for the in vitro membrane study falls in between 
the physiological doubling rate than 2D flask doubling rate. This could suggest 
that culturing cells on the thin amniotic membrane results in a semi-3D 
environment, but more experiments are required to strengthen the validity of this 
observation as discussed in the future aims section. 
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6. Conclusion 
SW-620 cancer cells were able to be seeded and proliferate onto the 
decellularized human amniotic membrane in in vitro culture studies. The cancer 
cells were able to form a nearly confluent monolayer on the surface of the 
amniotic membrane. SW-620 cells seeded on the amniotic membrane had a 
population doubling rate in between the doubling rate of an in vivo rat tumor 
model than the 2D flask culture. There are still unanswered questions regarding 
this study, including cell penetration and gene expression as well as improving 
the three dimensionality of the amniotic membrane. Cell penetration can be 
quantified through histology, gene expression can be determined and compared 
to in vivo conditions using PCR and the three dimensionality can be improved 
by layering the membrane and seeding cells between the layers. Though these 
questions need to be addressed further, the preliminary results regarding the 
monolayer growth of the SW-620 cells on the decellularized amniotic membrane 
were promising. 
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7. Future Aims 
There is more work needed in order to fully understand how these cells 
bind to the membrane and grow in longer time periods. Histology, successful 
fluorescent staining and Live/Dead assay would be useful to understand if there 
is any cellular penetration occurring through the membrane as well as cell 
viability. In order to have a viable 3D model, there must be cellular penetration 
and in turn, tumorigenesis. Staining and histology would be necessary to see the 
cellular penetration by repeating the five day study. PCR would also be useful to 
quantifying the cellular activity of the SW-620 cells growing in a monolayer 
versus a 3D in vitro model versus an in vivo animal model. Cells generally 
express different genes depending on their environment. Confirming that these 
cells are able to act like in vivo cells is necessary before moving forward with 
amniotic membrane as a scaffold and a clinically relevant model solution. 
According to literature, there are several genes that can be used to assess colon 
cancer behavior using RT-PCR. The housekeeping gene that can be used was 
glyceraldehyde-3-phosphate dehydrogenase (GADPH) [32]. There are 15 
relevant genes that can be examined. These genes are as follows: 
monocarboxylate transporter (MCT), human glutamate decarboxylase (GAD67), 
human serine proteinase inhibitor (P19), human glutathione transferase M3 
(GSTM3), human subunit C of V-ATPase (vat C), homo sapiens mRNA for 
translocation protein-1, human cyclin D (cyclin D1), human ataxia-
telangiectasia locus protein (ATM) gene, homo sapiens apoptosis-related protein 
TFAR15 (TFAR15), human CO-029, human surface antigen (ESA), homo 
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sapiens mRNA for ASM-like phosphodiesterase 3b, human interferon 
regulatory factor (Humirf5) and homo sapiens mRNA for IFN-inducible γ2 
protein. This is not a complete list of genes that can be monitored for the SW-
620 cell line but can be used as a starting point for RT-PCR monitoring. 
Repeating the five day study with PC-3 cells, MDA-MB-231 cells and 
other cancer cell lines would also be necessary to determine if the successful 
seeding and proliferation was cell-specific or can be repeated for different cell 
lines. The morphology of both of those lines is different than that of the SW-
620s and their reaction to the amniotic membrane needs to be documented. 
Additionally, repeating the experiments with natural (non-decellularized) 
membrane could be used as a control measure. This would determine if there is 
any significant changes between the decellularized and non-decellularized 
membrane and any interactions between the existing cells and cancer cells and 
could be explored further.  
Since the amniotic membrane is very thin in nature, surface 
modifications can be made to the membrane in order to expand into more 
sophisticated 3D models. Models involving larger scale 3D spaces resembling in 
vivo tumors require a larger scaffold capable of supporting cell growth in all 
three dimensions as opposed to only a monolayer. The amniotic membrane 
scaffold can be stacked in order to provide a larger scaffold. This scaffold can be 
seeded with cells in between the layers to promote cell penetration through the 
membrane to form an in vitro tumor. The type and extent of modifications 
depends on the results from the attachment of the other cancer lines to the 
42 
 
decellularized, unmodified membrane. Testing the other lines first will 
determine if modifications are necessary or if the cells bind to the amniotic 
membrane. This will also ensure that the seeding results determined using the 
SW-620 cells are not only cell-line specific and can be repeated with different 
cell lines. Further research is necessary to determine the adhesion mechanisms 
of cancer cells to each other and to other tissues. 
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9. Appendices 
Appendix 1: Standard curve for SW-620 DNA quantification 
 
Appendix 2: Standard curve for two day membrane experiment 
 
Appendix 3: Standard curves for five day membrane experiment 
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Day 0 and 1 
 
Day 2 and 3 
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Day 4 and 5 
 
Appendix 4: DNA Assay Protocol 
y = 617.1x + 13.347
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Appendix 5: Cell Splitting Protocol 
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Appendix 6: Tissue Preparation for a DNA assay 
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Appendix 7: PBS Preparation 
 
 
 
52 
 
 
Appendix 8: Media Preparation 
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Appendix 9: Cryogenically Freezing Cells 
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Appendix 10: Plating Cells from Cryopreservation 
 
Appendix 11: Counting Cells with the Hemocytometer 
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Appendix 12: Decellularization of the Amniotic Membrane 
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Appendix 13: SW-620 Culture in Flask (directly from cryopreservation) 
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Appendix 14: SW-620 Cells Culture in Flask (progression after splitting) 
 
Appendix 15: Glossary 
Glossary 
Amniotic membrane: Innermost, thin membrane of the placenta 
Cryopreservation: The state of freezing cells in liquid nitrogen at -196°C 
F-12k HAM: Media used to culture PC-3 cells 
Gleason score: A score quantified by a pathologist to classify prostate cancer 
In situ: In a localized state or condition [33] 
In vitro: Occurs in a laboratory vessel outside of the body [34] 
In vivo: Made to occur within a living organism [35] 
L-15: Media used to culture SW-620 and MDA-MB-231 cells 
MDA-MB-231: Breast cancer cell line obtained from ATCC 
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Nanopure water: Water with 18.2 megaohm ionic purity with negligible bacteria 
[36] 
PC-3: Prostate cancer cell line obtained from ATCC 
Quant-iT™ PicoGreen™ dsDNA Assay Kit: DNA assay kit used to determine 
concentration of DNA in a sample using absorbance 
RPMI-1640: Media used to culture PC-3 cells 
Seeding: Adding cells to a material or flask at a specific concentration and 
volume 
Sonication: Sound energy is applied to agitate particles in a sample 
Splitting: The action of lifting cells from a flask and moving them to new flasks 
for culture expansion 
Static culture: Culture conditions with no flow regime 
SW-620: Colon cancer cell line obtained from ATCC 
Tumorigenesis: Process of generating new tumors  
Appendix 16: Abbreviations 
Abbreviations 
ATCC: American Type Culture Collection 
ATM: Human ataxia-telangiectasia locus protein 
CO2: Carbon dioxide 
CSC: Cancer stem cell 
DMEM: Dulbecco’s minimal essential medium 
DMSO: Dimethyl sulfoxide 
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DNA: Deoxyribonucleic acid 
EGFR: Epidermal growth factor receptor 
EMT: Epithelial-to-mesenchymal transition 
ER: Estrogen receptor 
ESA: Human surface antigen 
GAD67: Human glutamate decarboxylase 
GAPDH: Glyceraldehyde-3-phostphate dehydrogenase 
GSTM3: Human glutathione transferase M3 
Humirf5: Human interferon regulatory factor 5 
MCT: Monocarboxylate transporter 
MSC: Mesenchymal stem cell 
ncRNA: Non-coding RNA 
P19: Human serine proteinase inhibitor 
PBS: Phosphate buffered saline 
PCR: Polymerase chain reaction 
PLLA: Poly-L-lactic acid 
PR: Progesterone receptor 
PSA: Prostate-specific antigen 
RNA: Ribonucleic acid 
TFAR15: Homo sapiens apoptosis-related protein TFAR15 
Vat C: Human subunit C of V-ATPase 
 
